Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (16409)	3/4/1998 2:51:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

Torben, I can't decide of your "16 YR REMARK" is due too the fact that you are cheap or a sexist pig. >)

To: Torben Noerup Nielsen who wrote (16409)	3/4/1998 3:22:00 PM
From: Alper H.YUKSEL	Read Replies (1) \| Respond to of 32384

<< >a sign of LGND planning to remain solely an R&D powerhouse What is so wrong with that? I honestly think there is a lot of money in that particular direction and I also believe LGND could go that way and make a bundle. I would not be at all surprised to see their R&D business remain a significant part of their earnings. >> Torben, My idea of an R&D powerhouse (and I might be wrong) is a company who does the research, is paid for it by the contract owners, gets milestone payments for advancing compounds and revenue percentages for the successful ones that have cleared all the clinicals. While the above approach has the benefits of ensuring a consistent revenue base as well as 'some' share of the revenues of successful drugs, with much less risk than would be the case with stand-alone biotech companies, it also places a cap on the upside potential IMHO. The above approach would not make LGND a $300 stock by 2006. With its own technologies and broad pipeline, I believe LGND is equipped well to venture to become a pharmaceutical company, rather than remain a top-notch R&D company. As for the investors, sure that's a higher risk, but I'd call it 'intelligent risk taking !' :) Regards Alper